Hualan Biological Vaccines, the vaccine unit of Chinese biopharmaceutical firm Hualan Biological Engineering (Hualan Bio), is raising a combined 2.07 billion yuan ($292 million) from Asia-focused private equity major Hillhouse Capital, and an investment vehicle led by Chinese investor Liu Xiaodan.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
